EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/422211
Tab ad page number FDA-approved, preservative- and bisulfi te-free OMIDRIA ™ (phenylephrine and ketorolac injection) 1% / 0.3% is the only treatment proven to maintain pupil size and reduce postoperative ocular pain in cataract surgery Maintains pupil size by preventing intraoperative miosis Signifi cantly reduces postoperative ocular pain Contains ketorolac (an NSAID) together with phenylephrine (a mydriatic agent) and is added to ophthalmic irrigation solution IS THE TIME TO PREVENT INTRAOPERATIVE MIOSIS AND REDUCE POSTOPERATIVE OCULAR PAIN Omeros ® and the Omeros logo ® are registered trademarks, and Omidria ™ and the Omidria logo ™ are trademarks, of Omeros Corporation. © Omeros Corporation 2014, all rights reserved. 2014-114 INDICATIONS AND USAGE OMIDRIA is an 1-adrenergic receptor agonist and nonselective cyclooxygenase inhibitor indicated for: Maintaining pupil size by preventing intraoperative miosis Reducing postoperative ocular pain OMIDRIA is added to an irrigation solution used during cataract surgery or intraocular lens replacement. IMPORTANT SAFETY INFORMATION OMIDRIA must be diluted prior to intraocular use. OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients. Systemic exposure to phenylephrine may cause elevations in blood pressure. Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other non-steroidal anti-infl ammatories (NSAIDs), or have a past medical history of asthma. The most common reported ocular adverse reactions at 2-24% are eye irritation, posterior capsule opacifi cation, increased intraocular pressure, and anterior chamber infl ammation. Use of OMIDRIA in children has not been established. Please see full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/ medwatch, or call 1-800-FDA-1088. CMS PASS-THROUGH STATUS EFFECTIVE JANUARY 1, 2015